GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Short Interest

Omeros (FRA:3O8) Short Interest


View and export this data going back to 2009. Start your Free Trial

What is Omeros Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Omeros's Short Interest

For the Biotechnology subindustry, Omeros's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Short Interest distribution charts can be found below:

* The bar in red indicates where Omeros's Short Interest falls into.


Omeros (FRA:3O8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Short Interest
Comparable Companies
VSTM ALDX PBYI CRMD INMB GOSS SYRS DRTS XOMA ZURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
OMER:USA 3O8:Germany
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Website
https://www.omeros.com
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines